396 related articles for article (PubMed ID: 24148258)
1. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD; Arnold A; Shepherd FA; Dediu M; Ciuleanu TE; Fenton D; Zukin M; Walde D; Laberge F; Vincent MD; Ellis PM; Laurie SA; Ding K; Frymire E; Gauthier I; Leighl NB; Ho C; Noble J; Lee CW; Seymour L
J Clin Oncol; 2010 Jan; 28(1):49-55. PubMed ID: 19917841
[TBL] [Abstract][Full Text] [Related]
4. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
[TBL] [Abstract][Full Text] [Related]
6. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
8. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F; Fenton D; Hirsh V; Zukin M; Stockler MR; Lee CW; Chen EX; Montenegro A; Ding K; Bradbury PA
Eur J Cancer; 2014 Mar; 50(4):706-12. PubMed ID: 24360368
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
12. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F
J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015
[TBL] [Abstract][Full Text] [Related]
16. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
